Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition.
Brain metastases
anti CTLA-4
anti-PD-1/PD-L1
checkpoint inhibitors
status epilepticus
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
29 11 2020
29 11 2020
Historique:
entrez:
10
12
2020
pubmed:
11
12
2020
medline:
29
7
2021
Statut:
epublish
Résumé
Integration of immune checkpoint inhibitors (ICIs) has improved the efficacy of treatment regimens for various cancers. The array of potential side effects keeps evolving and includes neurological complications. An increased risk of seizures and status epilepticus (SE) has been discussed and appears likely. In this report, we present clinical data from brain metastases patients undergoing ICI treatment revealing, for what we believe is the first time, SE as a serious adverse effect of ICI treatment. In our cohort of 3202 patients with brain metastases, we observed an increasing incidence of SE since the approval of ICIs in 2014 (16 patients in 2008-2013 vs. 36 patients in 2014-2019). Almost half of the patients treated in 2014-2019 received ICIs during the course of their disease, and in more than 80% of cases last dose of ICIs was given less than 30 days before SE. These findings suggest that ICIs may lead to an increased rate of SE in patients with brain metastases. Additional mechanistic research and prospective trials are necessary to elucidate the pathomechanism causing SE in patients treated with ICIs.
Identifiants
pubmed: 33299662
doi: 10.1080/2162402X.2020.1851517
pii: 1851517
pmc: PMC7714514
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Types de publication
Journal Article
Langues
eng
Pagination
1851517Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Case Rep Oncol. 2017 May 24;10(2):473-478
pubmed: 28626408
Lancet Oncol. 2016 Dec;17(12):e529-e541
pubmed: 27924751
Chin Clin Oncol. 2015 Jun;4(2):21
pubmed: 26112807
Epilepsia. 2019 Jan;60(1):42-52
pubmed: 30565664
Nat Rev Drug Discov. 2016 Apr;15(4):235-47
pubmed: 26965203
Ther Adv Neurol Disord. 2018 Sep 14;11:1756286418799864
pubmed: 30245744
Epilepsia. 2016 Dec;57(12):2056-2066
pubmed: 27753082
Ann Neurol. 2019 Mar;85(3):421-432
pubmed: 30661257
J Immunother Cancer. 2019 Jul 30;7(1):200
pubmed: 31362777
Epilepsia. 2012 May;53(5):e89-92
pubmed: 22462650
Pract Neurol. 2020 May;20(3):256-259
pubmed: 32303632
BMC Neurol. 2014 Jul 19;14:152
pubmed: 25037845
Expert Rev Neurother. 2015;15(9):1081-92
pubmed: 26312647
Epilepsia. 2015 Oct;56(10):1515-23
pubmed: 26336950
Lancet Neurol. 2015 Jun;14(6):615-24
pubmed: 25908090
J Neurol Neurosurg Psychiatry. 2006 May;77(5):611-5
pubmed: 16614020